The Key to a Successful Clinical Trial
In the article âThe Key to a Successful Clinical Trial,â published by World Pharma Today, Anne Marie Gaulin, Executive VP of International Expansion at Indero, discusses: The critical factors that influence the success of clinical trials. The piece covers essential topics such as patient recruitment and retention, regulatory compliance, and data integrity. Gaulin emphasizes the […]
Improving Patient Recruitment in Clinical Trials
In Bioscience Today, John Clarke, Associate Director in Patient Recruitment at Indero, provides an insightful analysis on improving patient recruitment in clinical trials. This article addresses: The challenges faced by pharmaceutical companies in enrolling participants, especially when existing treatments are well established. Clarke discusses the increasing regulatory expectations for diversity in trials and the importance […]
Embracing the Power of Data Analytics and AI for Clinical Trials
Inderoâs expertise is showcased in the article âEmbracing the Power of Data Analytics and AI for Clinical Trialsâ by News-Medical. The article covers: The increasing adoption of digital systems in clinical trials. The article highlights the integration of artificial intelligence and machine learning to enhance data management, streamline operations, and ensure high-quality results. It discusses […]
Harnessing AI and Data Analytics
The article âHarnessing Data Analytics and AI for Clinical Trials,â published by Applied Clinical Trials and authored by Guillaume Gigon, VP of Technology and AI at Indero, explores: The transformative impact of data analytics and artificial intelligence on clinical trials. The piece covers how these technologies are revolutionizing data management, enhancing operational efficiencies, and providing […]
The Future of CROs & Rheumatology
In this World Pharma Today interview, Inderoâs Chief Business Officer, Jason Shuris, reflects on how Contract Research Organizations (CROs) are evolving amid rapid changes in the lifeâscience industry. Shuris also discusses how scientific leadership, consistency of delivery, and a clear therapeutic focus position Indero as a differentiated partner for sponsors. By applying lessons learned from […]
Late-Breaking Data on Icotrokinra Shows Promising Efficacy and Safety in Psoriasis
At the recent American Academy of Dermatology (AAD) Annual Meeting, Robert Bissonnette, MD, presented late-breaking data from the ICONIC-LEAD (NCT06095115) study evaluating icotrokinra, an oral IL-23 receptor antagonist, for patients with moderate-to-severe plaque psoriasis. The phase 3 study demonstrated significant efficacy at week 16, with further improvements observed through week 24. In an interview with […]
Indero’s Leading Role and Experience in Propelling Dermatology Science Forward Showcased Once Again at the AAD 2025
Dr. Bissonnette, Indero’s Founder and Executive Chairman, alongside with peers, has authored the following abstract presented during this morning’s Late Breaking session at AAD: Tapinarof Cream 1% Once Daily: Maintenance of Low Disease Activity Including Pruritus Through End of the Treatment-free Interval in a Long-term Extension Trial in Patients Down to 2 Years of Age […]
How to Manage Placebo Response Rate in Atopic Dermatitis- Analyzing High Placebo-Response Rates
Welcome to the final installment of the series on placebo response rate in atopic dermatitis (AD). The first articles of this series shed light on the complexities and nuances of placebo response rates in AD and on strategies on how to ensure a reasonable response rate. This third and final article dives into the analysis of high placebo-response rates and […]
Dr. Bissonnette to Present ICONIC-LEAD Trial Results at AAD 2025 Late-Breaking Session 1
Dr. Robert Bissonnette, Innovaderm’s Founder and Executive Chairman, will be under the spotlight at AAD Annual Meeting on March 8, 2025, as he will be presenting the results of a phase III program entitled: Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23âReceptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Efficacy and Safety Results Through Week […]
Navigating AI in Healthcare: Expert Insights and FDA Draft Guidance
Navigating AI risks in healthcare just got easier with the FDA’s new draft guidance and explanations from Guillaume Gigon, Innovaderm’s VP of Technology and AI. You can even comment on the FDA draft document by April 7. Watch the video here!
